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ABSTRACT:
Loss of secreted phospholipase A2 receptor (PLA2R1) has recently been found to 
render human primary cells more resistant to senescence whereas increased PLA2R1 
expression is able to induce cell cycle arrest, cancer cell death or blockage of cancer 
cell transformation in vitro, suggesting that PLA2R1 displays tumor suppressive 
activities. Here we report that PLA2R1 expression strongly decreases in samples 
of human renal cell carcinoma (RCC). Knockdown of PLA2R1 increases renal cancer 
cell tumorigenicity supporting a role of PLA2R1 loss to promote in vivo RCC growth. 
Most RCC result from Von Hippel-Lindau (VHL) tumor suppressor loss-of-function and 
subsequent gain-of-function of the oncogenic HIF-2alpha/c-MYC pathway. Here, by 
genetically manipulating VHL, HIF-2alpha and c-MYC, we demonstrate that loss of 
VHL, stabilization of HIF-2alpha and subsequent increased c-MYC activity, binding 
and transcriptional repression, through induction of PLA2R1 DNA methylation closed 
to PLA2R1 transcriptional start site, results in decreased PLA2R1 transcription. 
Our results describe for the first time an oncogenic pathway leading to PLA2R1 
transcriptional repression and the importance of this repression for tumor growth. 
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INTRODUCTION
The secreted phospholiapse A2 receptor (PLA2R1) 
belongs to the mannose receptor family. It binds several 
secreted phospholipases A2 (sPLA2s) and various 
collagens and carbohydrates [1-5]. We have previously 
discovered that in normal human cells, loss of the 
phospholipase A2 receptor (PLA2R1) delays senescence 
or favors senescence escape, depending on the stress [6, 
7], senescence being a tumor suppressive pathway [8-13]. 
In addition, PLA2R1 knockout mice are more prone to 
form tumors induced by RAS [7]. These tumor suppressive 
effects of PLA2R1 are at least in part mediated by 
increased JAK2 activity and increased ROS production 
[6, 7, 14]. Together these results strongly support a 
tumor-suppressive activity of PLA2R1. Nevertheless, the 
mechanisms regulating PLA2R1 expression are currently 
unknown.
Analysis in the Oncomine database, a cancer 
microarray database allowing to perform differential 
expression analyses comparing most major types of cancer 
with respective normal tissues, shows that numerous 
cancers display an unusually low PLA2R1 mRNA level 
[7]. Amongst these cancers, kidney cancers are the one 
displaying the strongest decrease. In addition, PLA2R1 
has recently been described as an important protein in 
kidney physiopathology [15], we have then decided to 
investigate whether it might play a tumor-suppressive 
role in kidney cancer. The most frequent and aggressive 
renal cancer is conventional renal cancer or clear cell 
Renal Cell Carcinoma (RCC). These highly vascularized 
tumors, either sporadic or familial, are strongly associated 
with biallelic inactivation of the Von Hippel-Lindau gene 
(VHL), by point mutation, loss of heterozygosity, and/or 
promoter methylation [16]. The VHL tumor suppressor 
is an E3-ubiquitin ligase recognizing regulatory proteins 
such as the alpha subunits of the Hypoxia Inducible 
Factors (HIFs), the interaction being followed, generally, 
by ubiquitination and proteasomal degradation of the 
partner. Loss of VHL in RCC thus results in increased 
HIFα stability. This stabilization of HIFα proteins, 
particularly HIF2α, is thought to be a driving force of 
RCC initiation and progression [17, 18].
We have thus investigated the possibility that 
PLA2R1 might play a role in regulating kidney cell 
transformation and RCC growth and have examined how 
its expression might be related to the VHL pathway.
RESULTS
PLA2R1 expression is lost in clear cell renal cell 
carcinoma
To examine whether PLA2R1 might exert tumor-
suppressive activity in RCC, we first analyzed transcript-
Figure 1: PLA2R1 expression decreases in clear cell renal cell carcinoma. (A) RNAs were extracted from both normal and 
cancer tissues from the same patients (n=16) and PLA2R1 transcript levels were assayed by qRT-PCR and normalized against PPIA. (B) 
Photograph representative of 100% of the analyzed samples (n=27), PLA2R1 immunostaining of RCC. (C) Photograph representative of 
40% of the analyzed samples (n=27), PLA2R1 immunostaining of normal renal tubules. The asterisk shows the PLA2R1 staining in some 
normal renal tubules. 
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level PLA2R1 expression in normal and RCC tissue 
samples. Strikingly, the PLA2R1 mRNA level was 
markedly lower in RCC tissue samples than in their 
normal counterparts (Figure 1A). This transcript-level 
down regulation led us to look at the protein level. Using 
a tissue microarray comprising twenty-seven pT3 RCC 
tumor tissue samples as described in [21], we found 
PLA2R1 to be undetectable in all the RCC tumor tissues 
(Figure 1B). In contrast, the protein was detected in the 
normal tissue in 40% of the examined samples, in the cells 
from which RCC originates: cortical tubular epithelial 
renal cells (Figure 1C) [25].
A PLA2R1 decrease accelerates RCC growth in 
mice
As PLA2R1 levels strongly decreased in RCC, 
we next examined whether PLA2R1 down regulation 
might influence RCC tumor growth. To this end we 
generated stable PLA2R1-knockdown ACHN cells, using 
two different PLA2R1-targeting shRNAs (Figure 2A). 
PLA2R1-knockdown ACHN cells displayed increased 
transformation ability, as demonstrated by their capacity 
to form more and bigger colonies than control ACHN 
cells in soft agar (Figure 2B). Next, control or PLA2R1 
knockdown ACHN cells were injected subcutaneously 
into nude mice and tumor growth was monitored for 47 
days after grafting. PLA2R1 knockdown was found to 
increase tumor growth significantly, the average tumor 
volume reaching about three times that of control tumors 
(Figure 2C-D and Supplementary Figure S1).
 We next investigated the mechanism of this 
tumor growth acceleration by analyzing proliferation 
and cell death in the xenograft tumors. Ki-67 staining 
revealed a significant increase in proliferation in response 
to PLA2R1 depletion (Figure 2E-F), whereas TUNEL 
assays revealed no impact of PLA2R1 depletion on cell 
death (Figure 2G).
Figure 2: PLA2R1 knockdown favors RCC-derived cell tumorigenicity. The ACHN cell line was infected with a control or 
PLA2R1-targeting shRNA and infected cells were puromycin selected. (A) RNAs were prepared and reverse-transcribed. Quantitative PCR 
was performed to measure the relative PLA2R1 mRNA level, normalized with respect to the ACTB level, in each indicated condition. (B) 
Twenty-five thousand ACHN cancer cells were seeded into agar and allowed to grow for 2 weeks. After 2 weeks, colonies were counted 
for each indicated condition and representative photographs are displayed (mean±SD, 3 independent experiments). (C) Five million ACHN 
cells infected with a control or PLAR1-targeting shRNA vector were grafted into the right flanks of 7-week-old nude mice. Tumor growth 
was monitored with a caliper. Tumor volume was calculated as V= LxlxH/2. Statistical analysis was performed with a T-test and the results 
are shown in Supplementary Figure 1. (D) Photographs show for each condition a representative picture of a tumor at necropsy. Scale 
bar represents 1 cm. (E-G), Control and PLA2R1-knockdown ACHN-derived tumors were collected, fixed, and embedded. Tumor tissue 
sections were used to analyze proliferation and cell death for each experimental condition. (E) Immunohistochemical detection of the Ki-67 
proliferation marker. Nuclei were counterstained with hematoxylin. Ki-67-positive cells were counted in at least four independent fields per 
tumor in at least three independent tumors. (F) Representative photographs are shown. (G) TUNEL assays were performed to label dying 
cells. After Hoechst staining of the nuclei, the percentage of TUNEL-positive cells was calculated for each condition and normalized with 
respect to the control value (at least 3 independent tumors and at least 4 independent fields/tumor were analyzed). 
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Constitutive PLA2R1 expression inhibits RCC 
growth in mice
The above observation that decreasing PLA2R1 
improves growth of RCC tumors led us to examine the 
effect of constitutively expressing PLA2R1 in RCC cell 
lines (ACHN and 786-O). We first infected these cells with 
a control (ctrl) or a PLA2R1 encoding retroviral vector 
and checked for constitutive PLA2R1 expression (Figure 
3A and Supplementary Figure S2A). Constitutive PLA2R1 
expression was found to strongly inhibit the ability of 
ACHN and 786-O cells to form clones in soft agar (Figure 
3B and Supplementary Figure S2B). 786-O-derived 
tumors grew rapidly in mice, but this tumor growth was 
slowed down when PLA2R1 was constitutively expressed 
(Supplementary Figure S2C-E). Importantly, the slow 
growing ACHN derived tumors responded strongly to 
constitutive PLA2R1 expression: after reaching a mean 
size of 161 mm3, they were found to regress (Figure 
3C-D and Supplementary Figure S3). We conclude that 
constitutive PLA2R1 expression delays or blocks RCC 
xenograft growth, depending on the implanted cells.
 In 786-O and ACHN derived tumors, constitutive 
expression of PLA2R1 was found to affect tumor growth 
both by decreasing cell proliferation (as estimated by 
Ki-67 staining, Figure 3E-F and Supplementary Figure 
S4A-B) and increasing cell death (as estimated in TUNEL 
assays, Figure 3G-H and Supplementary Figure S4C-D). 
Together, these data provide the first evidence that 
increasing the PLA2R1 level causes tumor-suppressive 
effects in RCC.
VHL loss of function decreases PLA2R1 levels in 
RCC
Having observed that PLA2R1 is lost in human 
RCC samples and that PLA2R1 deregulation strongly 
impacts RCC tumor growth, we next investigated the 
mechanism regulating PLA2R1 expression in RCC. The 
development of most RCCs involves inactivation of 
the VHL tumor suppressor gene by one or more of the 
following mechanisms: genetic mutation in the coding 
region, loss of heterozygosity, promoter hypermethylation 
[16]. As the twenty-seven RCC samples examined in the 
TMA showed no detectable PLA2R1 protein, we next 
investigated whether PLA2R1 might be a downstream 
target of VHL. First we measured PLA2R1 mRNA levels 
in five characterized RCC cell lines. ACHN cancer cells 
Figure 3: PLA2R1 expression inhibits transformation and decreases tumor growth. ACHN cells were infected with a 
control or PLA2R1-encoding vector. Infected cells were next puromycin selected. (A) Ectopic expression of PLA2R1 was analyzed by 
western blotting. Tubulin was used as a loading control. (B) Twenty-five thousand ACHN cells were seeded in agar and allowed to grow. 
After 2 weeks, colonies were counted for each indicated condition and representative photographs are displayed (mean±SD, 3 independent 
experiments). Histograms show an experiment representative of 3 independent experiments. Statistics were performed with the T-test. *** 
represents a p value< 0.005. (C) Five million ACHN cells were grafted into the right flanks of 7-week-old nude mice. Tumor growth was 
monitored with a caliper. Tumor volume was calculated as V= LxlxH/2. Statistical analysis was performed with a T-test and the results are 
shown in Supplementary Figure 3. (D) Photographs show a picture of tumors at necropsy for each condition. Scale bar represents 1cm. (E-
H) Control and PLA2R1-expressing ACHN-derived tumors were collected, fixed, and embedded. Tissue sections from tumors were then 
used to analyze proliferation and cell death. (E-F) Immunohistochemistry against Ki-67 proliferation marker was performed. Nuclei were 
counterstained by an hematoxylin solution. (E) Histogram representing the percentage of Ki-67 positive cells was displayed. Positive cells 
were counted on at least 4 independent fields per tumor and at least 3 independent tumors. (F) Representative photographs are shown. (G-
H) TUNEL assays were performed to label dying cells. After nuclear staining with Hoechst dye, the percentage of TUNEL positive cells 
was calculated (at least 3 independent tumors and at least 4 independent fields/tumor analyzed). (G) TUNEL-positive cell percentages are 
presented relatively to control cells. (H) Images are shown. 
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are known to express a functional VHL, whereas Caki-
2, 786-O, RCC4, and RCC10 cells express a mutated 
nonfunctional VHL protein. Interestingly, a higher 
PLA2R1 mRNA level was found in VHL functional 
ACHN cells than in any of the VHL nonfunctional cancer 
cell lines (Figure 4A). 
Functional confirmation that PLA2R1 is positively 
regulated by VHL was obtained by engineering VHL 
negative RCC10 and 786-O cells to express the VHL gene 
constitutively (the resulting cells are respectively named 
RCC10+VHL and 786-O+VHL cells): both engineered 
RCC cell lines showed an increased PLA2R1 transcript 
level (Figure 4B-C).
 VHL exerts its tumor-suppressive activity by 
inducing degradation of HIFα proteins, but it might 
also exert HIF-independent activities [17, 18, 26]. To 
determine whether HIFα protein degradation is involved 
in VHL-induced PLA2R1 transcription, we examined 
PLA2R1 transcript levels in ACHN (Figure 4D), 
RCC10+VHL (Figure 4E), and 786-O+VHL cells (Figure 
4F) constitutively synthesizing a non-degradable form of 
either HIF1α or HIF2α [20]. Constitutive expression of 
HIF2α strongly reduced PLA2R1 mRNA level in all three 
cases. Forced HIF1α showed less marked effects (Figure 
4D-F).
Together these data demonstrate that PLA2R1 
expression is regulated by VHL, and that VHL loss of 
function in RCC results in PLA2R1 loss of expression, 
mainly through an HIF2α dependent mechanism.
An HIF2α-MYC repressive pathway, downstream 
of VHL loss of function, mediates PLA2R1 
repression in RCC
Even if HIF2α is generally described as a 
transcriptional activator, it has also been reported to 
repress transcription [27]. Chromatin immunoprecipitation 
(ChIP) experiments performed on 4 independent PLA2R1 
genomic regions (Figure 5A) revealed no direct binding of 
Figure 4: VHL regulates PLA2R1 expression in RCC-
derived cells. (A) PLA2R1 transcript levels were assayed by 
qRT-PCR and normalized against ACTB in five RCC cell lines: 
ACHN, Caki-2, RCC4, RCC10, and 786-O. VHL function 
is indicated for each cell line. (B) PLA2R1 transcript levels 
were assayed by qRT-PCR and normalized against ACTB in 
786-O and (C) RCC10 control or constitutively expressing 
VHL. Histograms show an experiment representative of three 
independent experiments. (D-F) Cells were infected with a 
control retroviral vector or one encoding a VHL-resistant 
HIF1α mutant or a VHL-resistant HIF2α mutant. Infected cells 
were puromycin-selected. RNAs were prepared and reverse 
transcribed. Quantitative PCR was performed against PLA2R1 
and normalized with respect to the ACTB mRNA level in (D) 
ACHN cells, (E) in RCC10+VHL cells and (F) in 786-O+VHL 
cells as indicated. 
Figure 5: An HIF2α-MYC pathway represses 
PLA2R1 expression. (A) Schematic representation of 
the PLA2R1 genomic regions tested for HIF2α binding. (B) 
Binding of HIF2α on PLA2R1 genomic regions was assayed 
by chromatin immunoprecipitation. ChIP was performed on 
786-O+VHL+HIF2α cells and PCR performed on the input and 
bound fractions. PHD3 was used as positive control for HIF2α 
binding and 4 genomic regions of PLA2R1 were assayed. (C) 
Binding of c-MYC on PLA2R1 genomic regions was assayed 
by chromatin immunoprecipitation. ChIP was performed on 
786-O+VHL+HIF2α cells and PCR performed on the input 
and bound fractions. Four genomic regions of PLA2R1 (PR1 to 
PR4) were assayed. (D) 786-O+VHL cells were infected with a 
control or a c-MYC encoding retroviral vector and puromycin 
selected. Five days later, RNA were prepared and retro 
transcribed. Quantitative PCR was performed against PLA2R1 
and normalized with respect to the ACTB mRNA level.
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HIF2α, whereas and as expected it was found to bind 
PHD3 [23], a direct HIF2α target (Figure 5B).
HIF2α exerts its oncogenic activity by increasing 
c-MYC transcriptional activities, the activating as well as 
the repressing ones [28, 29]. To check whether c-MYC 
might be a downstream effecter of HIF2α to repress 
PLA2R1 expression, we immunoprecipitated c-MYC 
DNA-bound regions in HIF2α-overexpressing cells, cells 
in which PLA2R1 expression is repressed (Figure 4F). 
Interestingly, c-MYC was bound to PLA2R1 genomic 
regions closed to the transcriptional start site (PR1 and 
PR2) and not to distal PLA2R1 genomic regions (PR3 and 
PR4) (Figure 5C). Further supporting a repressive role of 
c-MYC on PLA2R1 expression, its constitutive expression 
was found to inhibit PLA2R1 expression in 786-O+VHL 
cells, cells in which PLA2R1 is induced (Figure 5D). 
These data demonstrate a pathway involving loss of VHL, 
increased HIF2α and c-MYC activity leading to PLA2R1 
repression in RCC.
The VHL-HIF-MYC pathway regulate PLA2R1 
expression through DNA methylation
C-MYC represses transcription by various 
mechanisms including DNA methylation [30, 31]. 
Interestingly, PLA2R1 has recently been shown to be 
repressed by DNA methylation in leukemic cells [32] 
pointed out a potential mechanism by which the VHL-
HIF2α-MYC pathway might regulate PLA2R1 expression 
in RCC. 
 To know whether the expression of PLA2R1 
might be regulated by DNA methylation, we treated 
VHL-positive (ACHN) and -negative (RCC10 and 786-
O) derived RCC cell lines with the 5-azadeoxycytidine 
(5-aza-dC) DNA methyl transferase (DNMT) inhibitor. 
Both VHL-negative cell lines displayed a strong PLA2R1 
induction upon DNMT inhibition by contrast to the 
VHL-positive cell line (Fig. 6A). This suggests that the 
repressive VHL-HIF2α-MYC pathway regulates PLA2R1 
expression through DNA methylation.
 We next carried out bisulphite genomic 
sequencing to compare PLA2R1 methylation in ACHN 
cells (VHL-positive, PLA2R1-positive), 786-O cells 
(VHL-negative, PLA2R1-negative) and 786-O+VHL cells 
(PLA2R1 positive). CpG methylation were examined in 
a PLA2R1 region spending from -378 to +497, a region 
overlapping the c-MYC binding regions as seen in the 
figure 5C. CpG island hypermethylation was observed 
in PLA2R1-negative 786-O cells. By contrast, this island 
was not methylated after forced VHL expression in these 
cells or in VHL-positive ACHN cells further suggesting 
that this repressive pathway is acting by controlling DNA 
methylation on PLA2R1 promoter.
DISCUSSION
Clear cell renal cell carcinoma represents 80% of 
all renal cancers and is the most aggressive and deadly 
one. We show here that PLA2R1 is lost in RCC and 
that this loss might be an important event increasing 
RCC growth as its decrease accelerates tumor growth in 
nude mice. We have also examined the effect of using 
cells constitutively expressing PLA2R1 in nude-mouse 
xenograft RCC models, using two different RCC-derived 
cell lines (ACHN or 786-O) to generate the tumors. In 
both cases the implanted cells show a reduced tumor-
promoting potential, due both to induce cell death and 
slower proliferation. Most interestingly, the slow-growing 
ACHN-derived tumors, after some initial tumor growth, 
are regressing. This suggests that restoring this pathway 
might be an effective way to trigger RCC regression.
A major step in the initiation of the RCC is the 
VHL tumor-suppressor gene inactivation. PLA2R1 
expression correlates with loss of VHL tumor-suppressor 
function, and restoring VHL expression is sufficient to 
restore PLA2R1 expression in RCC-derived cell lines. 
Our observation support the view that this effect of VHL 
Figure 6: The VHL-HIF2α-MYC regulates PLA2R1 expression through its DNA methylation. (A) Indicated RCC-derived 
cell lines were treated with or without 5-aza-dC at 5µM during 24 hrs. RNA were prepared, retro-transcribed and PCR performed against 
PLA2R1 or ACTB as loading control using the primers described in [7]. (B) Genomic DNA of the indicated cells were prepared and 
subjected to sodium bisulphate modification. PCR was performed to amplify the indicated regions. The amplified regions were subcloned 
and sublconed fragments were sequenced to determine whether or not the CpG were methylated.
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depends mainly on its ability to degrade its HIF2α target 
and not HIF1α. HIF2α and HIF1α are both down regulated 
by VHL. Although it was initially thought that the two 
proteins share common pro-tumor functions, recent 
data suggest some specificity for each protein, in terms 
of transcriptional targets and interacting proteins [33]. 
Importantly HIF2α,  unlike HIF1α, is now viewed as a key 
oncogenic actor in RCC, particularly through its ability to 
increase c-MYC activity [28, 29].
HIF2α is unable to bind PLA2R1 genomic regions 
suggesting that HIF2α indirectly represses PLA2R1. 
Transcriptional repression by c-MYC of genes blocking 
tumor growth such as p21 and p27 CKIs is part of its 
pro tumoral program [28]. c-MYC, which is known 
to mediate HIF2α oncogenic effect, is thus a good 
candidate to mediate HIF2α-induced PLA2R1 repression. 
Confirming this hypothesis, c-MYC binds PLA2R1 
genomic regions closed to PLA2R1 transcription start site 
and its forced expression represses PLA2R1 expression. 
C-MYC is known to repress transcription by recruiting 
various repressive complexes including the DNA methyl 
transferases (DNMT), the enzymes that methylate the 
CpG [30, 31] and PLA2R1 has recently been found to 
be methylated,[32] suggesting that c-MYC might exert 
its repressive activity through induction of PLA2R1 
DNA methylation. Indeed, inhibiting the DNMT in cells 
expressing low levels of PLA2R1 is sufficient to restore 
PLA2R1 expression. In addition, PLA2R1 promoter 
methylation is observed when VHL is not functional; 
then when the HIF2α-MYC pathway exerts its repressive 
activity. By contrast, PLA2R1 CpG island methylation is 
lost when VHL is functional; then when the HIF2α-MYC 
pathway is off and unable to exert its repressive activity 
on PLA2R1.
In conclusion, our study report novel findings 
showing that PLA2R1 is repressed in RCC by the loss of 
VHL tumor suppressor and the activation of the oncogenic 
HIF2α-c-MYC pathway and that repression favors RCC 
tumorigenecity.
MATERIALS AND METHODS
Cell Culture
The human kidney cancer cell lines ACHN, Caki-
2, RCC4, RCC10, and 786-O were obtained from ATCC 
and virus-producing GP293 cells from Clontech. VHL-
expressing RCC4, RCC10, and 786-O cells have been 
described in [19]. Cell lines were cultured in DMEM 
(Invitrogen) containing Glutamax and supplemented 
with 10% FBS (Lonza) and 1% penicillin/streptomycin 
(Invitrogen). Upon receipt, cells were thawed, amplified 
and aliquots frozen. Experiments were performed from 
these aliquots within a 4 months period without further 
authentication of the cell lines.
Vectors
Human wild-type membrane-bound PLA2R1 
(GenBank NM 007366) was generated by PCR from 
the PLA2R1-encoding pSupF vector and ligated into 
the pGEMTeasy vector (Promega), fully sequenced, and 
subsequently subcloned in the pLPCX retroviral vector 
(Clontech) between XhoI/NotI restriction sites. PLA2R1-
shRNA-encoding retroviral vectors have been described 
in [6]. The following vectors were supplied by Addgene: 
pBabe-VHL [19] (# 19234), pBabe-HIF-1α P402A/P564A 
(#19005), pBabe-HIF2αP405A/P531A (#19006) [20]. 
Immunohistochemistry
The RCC study was performed on 4-µm-thick 
sections from a tissue microarray comprising 27 formalin- 
and paraffin-embedded RCC tumor tissue samples, each 
with the surrounding  morphologically benign-appearing 
renal parenchyma.[21] Heat antigen retrieval was done 
in citrate buffer pH 6 in a pressure cooker. Endogenous 
peroxidase was blocked by addition of H2O2. Incubation 
with PLA2R1 antibody was carried out overnight at 
4°C. In the negative control, the primary antibody was 
omitted [15]. In the xenograft experiments, fresh tumors 
were fixed for 48 h in 10% neutral buffered formalin 
(Sigma). Paraffin-embedded sections were treated with 
unmasking solution (VectorLABS) and exposed to H2O2 
to block endogenous peroxidase activity. For Ki-67 
staining, tumor sections were incubated with an antibody 
directed against Ki-67 antigen (Dako), a biotinylated 
secondary antibody (Dako), and streptavidin-HRP solution 
(Dako). Nuclei were counterstained with hematoxylin 
solution (Sigma) and analyzed by light microscopy. For 
TUNEL assays, tumor sections were treated with 4% 
PFA and 0.2% PBS-Triton and then incubated with TdT 
enzyme and biotinylated dUTP (Roche) according to 
the manufacturer’s instructions. Biotinylated DNA was 
detected with Cy-3-coupled streptavidin (Interchim). 
Nuclei were stained with Hoechst dye (Sigma). Samples 
were analyzed by fluorescence microscopy.
Soft-agar and xenograft experiments
To measure anchorage-independent growth, cells 
were detached with trypsin and suspended in growth 
medium. Base agar was prepared with 0.75% low-
melting agarose (Lonza) in growth medium. The top 
agar contained the cells suspended in 0.45% low-melting 
agarose (1.25-2.5x104 cells/well in 6-well plates, for 786-
O and ACHN respectively). Plates were incubated for 1 
(786-0) or 2 weeks (ACHN) and colonies were counted 
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under a bright light microscope.
For the xenograft experiments, 5x106 control or 
modified cells in 200 µl  PBS/Matrigel (BD Biosciences) 
(3/1, v/v) were injected subcutaneously into the right 
flanks of 6-week-old female athymic nude mice (nu/
nu). Tumor size was measured with an electronic 
caliper, weekly or at sacrifice. Tumor volume (V) was 
calculated using the following formula: V=axbxc/2, 
where “a” is the longest diameter, “b” is the shortest one, 
and c the depth. Numbers of mice with size details and 
statistics are indicated in Supplementary Figures. The 
mice were housed and bred in the specific pathogen-
free animal facility AniCan at the CRCL, Lyon, France. 
The experiments were performed in accordance with the 
animal care guidelines of the European Union and with 
French legislation and were approved by the local Animal 
Ethics Evaluation Committee (CECCAPP).
Transfection and infection
To transfect GP293 cells, PEI reagent was used 
according to the manufacturer’s recommendations 
(Euromedex). Two days after transfection, the viral 
supernatant mixed with fresh medium (1/2) and polybrene 
(final concentration: 8ug/mL) was used to infect target 
cells. The cells were infected for 12-24 h depending on 
the cell type. Importantly, the infection protocols were 
designed so that practically all the cells were infected, 
as judged by the results of infection with a GFP control. 
One day post-infection, cells of each cell line used 
were selected with the appropriate antibiotic at the final 
concentration of 500 ng/ml. 
Immunoblots
Cell lysates were prepared in Laemmli buffer 
(50mM Tris·HCl, pH 7.4, 250mM NaCl, 0.2% Triton 
X-100, 5mM EDTA) supplemented with protease and 
phosphatase inhibitors (Roche). Lysates were clarified by 
centrifugation at 14,000 rpm for 30 min at 4°C. Protein 
concentrations were measured by means of the Bradford 
protein assay (Biorad #500-0006). Cell extracts were 
resolved by SDS-PAGE under non-reducing conditions 
for PLA2R1 detection or reducing conditions for detection 
of other proteins and transferred onto nitrocellulose 
membranes. For detection, the following primary 
antibodies were used: anti-PLA2R1 [15], anti-tubulin 
(T6199, Sigma). After overnight incubation at 4°C with 
primary antibodies, the blots were washed with PBS 
containing 0.05% Tween, incubated with a peroxidase-
coupled secondary antibody, and washed again in PBS 
containing 0.05% Tween. Antigen-antibody complexes 
were detected by ECL (Amersham).
RNA extraction, reverse transcription, and PCR
Normal and tumoral human kidney tissues were 
provided by the biobank of the CHU of Lille. Phenol-
chloroform total RNA extraction was performed with 
TriReagent (Sigma-Aldrich, Saint Louis, MO, USA). 
PhaseLockGel tubes (Eppendorf, Hamburg, Germany) 
were used for phase separation. cDNA was synthesized 
from 3 µg total RNA with the First-Strand cDNA 
Synthesis Kit (GE Healthcare, Chalfont St Giles, UK). 
The RT reaction mixture was diluted 1/60 and used as 
cDNA template for qPCR analysis. TaqMan quantitative 
PCR analysis was carried out on a LightCycler 2.0 
System (Roche Applied Science). PCR mixtures contained 
LightCycler TaqMan mix, 200 nM primers, and 1.67 μl 
cDNA template in a 6.67-μl reaction volume. The PPIA 
or ACTB housekeeping gene, as indicated, was used in 
kidney samples for normalization of PLA2R1 mRNA 
expression in each sample type. Intron-spanning real-time 
PCR assays were designed with the ProbeFinder software 
(Roche Applied Science). All real-time PCR primers are 
listed in Supplementary Table 1.
Chromatin Immunoprecipitation (ChIP) 
experiments
ChIP experiments were performed as described 
in [22] using about 30 millions of 786-0+VHL+HIF2α 
growing cells. HIF2α [23] or c-MYC (sc-764 X, Santa 
Cruz Biotechnology) specific antibodies were used for the 
immunoprecipitation. PCR primers for quantitative PCR 
are listed in Supplementary Table 2.
Bisulphite genomic sequencing
Sodium bisulphite reactions were carried out as 
previously described in [24]. Two regions (nt positions 
−378 to +71, and nt positions +45 to +497 from the 
PLA2R1 transcription start site) were analyzed. PCR 
amplifications were performed in 100 µl using the 
HotStart Taq DNA polymerase Kit (Qiagen) and 0.25 µM 
of the primers (Supplementary Table S3), after 15 min at 
95°C for Taq polymerase activation and 35 cycles (0.5 
min denaturation at 94°C, 1 min annealing at 52°C, and 
1.5 min extension at 72°C). To determine accurately the 
proportion of methylated CpG, PCR products were cloned 
into a pGEM-T vector (Promega) and random clones were 
analyzed by automatic sequencing (Genomics, Beckman 
Coulter).
Statistics
Graphs are presented with SD as error bars, and 
Student’s t test was used to determine the p value (* p< 
Oncotarget1012www.impactjournals.com/oncotarget
0.05; ** p< 0.01; *** p< 0.001) unless indicated otherwise 
in the figure legends.
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